FindTrial
Sign In

Study of Nitazoxanide (NTZ) for Helicobacter Pylori in Children

Study of Novel Triple Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori in Children

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04415983
Enrollment
100
Registered
2020-06-04
Start date
2020-06-01
Completion date
2030-12-01
Last updated
2020-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori Infection

Brief summary

Study of Nitazoxanide (NTZ) based therapeutic regimens for Helicobacter pylori in children

Detailed description

Study of Novel triple Nitazoxanide (NTZ) based new therapeutic regimens for Helicobacter pylori in children

Interventions

DRUGNitazoxanide

Nitazoxanide twice daily

DRUGClarithromycin

Klacid twice daily

DRUGMetronidazole

Metronidazole twice daily

DRUGProton pump inhibitor

Omeprazoe twice daily

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

\- Positive helicobacter infection.

Exclusion criteria

* Previous treatment for H. Pylori.

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with cured helicobacter infection6 monthsTotal number of patients with eradicated helicobacter infection

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, ass. prof.
sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026